Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial

IMPORTANCE: Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising resu...

全面介紹

Na minha lista:
書目詳細資料
發表在:JAMA Oncol
Main Authors: He, MinKe, Li, QiJiong, Zou, RuHai, Shen, JingXian, Fang, WanQiang, Tan, GuoSheng, Zhou, YuanMin, Wu, XiaoPing, Xu, Li, Wei, Wei, Le, Yong, Zhou, ZhongGuo, Zhao, Ming, Guo, Ying, Guo, RongPing, Chen, MinShan, Shi, Ming
格式: Artigo
語言:Inglês
出版: American Medical Association 2019
主題:
Original Investigation
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512278/
https://ncbi.nlm.nih.gov/pubmed/31070690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0250
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍